Eisai, Arena to launch obesity drug next month

05/9/2013 | PharmaTimes (U.K.)

Eisai and Arena Pharmaceuticals plan to launch their antiobesity drug Belviq, or lorcaserin, in the U.S. next month following the drug's classification as a Schedule IV controlled substance. Belviq was approved by the FDA last year for chronic weight management in obese adults who suffer from at least one weight-related condition. The launch triggers the payment of a $65 million milestone fee from Eisai to Arena.

View Full Article in:

PharmaTimes (U.K.)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Senior director risk adjustor and coding doc
Novant Health
Charlotte, NC
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
BCBS-Louisiana
Baton Rouge, LA